“Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of Covaxin in additional secondary study endpoints,” the company further said in its statement.
“Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participant,” Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech said about the announcement.
He added that the vaccine showed high clinical efficacy trend not just against COVID-19 but also “significant immunogenicity against the rapidly emerging variants.”
Meanwhile, Indian Council of Medical Research (ICMR), which backed the vaccine and jointly conducted the trials, said that the results had been evaluated by an independent data safety and monitoring board. It showed that…